Stay updated

RITEDOSE In the News

For press inquiries: teamritedose@mcalistercommunications.com

For press inquiries: teamritedose@mcalistercommunications.com

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)

COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)

COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: Sodium Chloride 23.4% (120mEq/30 mL)

COLUMBIA, S.C. (August 11, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Sodium Chloride 23.4% (120mEq/30 mL). It is the 10th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Releases Two New Single-Dose Syringe Products for Hospital Pharmacies: Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL)

COLUMBIA, S.C. (May 21, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL). These are part of a six-month, 12-product rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Brings New Unit Dose Syringe Product to the Market: Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL)

COLUMBIA, S.C. (May 14, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches New Single-Dose Syringe Product: Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL)

COLUMBIA, S.C. (April 30, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Releases Two New Single-Dose Syringe Products to the Market: Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL)

COLUMBIA, S.C. (April 16, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL). These are part of a 12-product rollout expected from Ritedose over the next six months for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »

Ritedose Launches Two New Single-Dose Syringe Products: Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) & Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL)

COLUMBIA, S.C. (April 2, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) and Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL). These are part of a 12-product rollout expected from Ritedose over the next six months for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

Read More »
Shape
Shape

Improving the medication experience

From Particles To Patients